If only
Indivior (LSE: INDV) is a pharmaceutical company that specialises in producing Suboxone, a prescription drug for the treatment of patients who are dependent on opioids. The firm operates in 40 countries worldwide. It was set up in 1994 as the pharmaceuticals division of consumer goods giant Reckitt Benckiser, but was spun off in December 2014 and listed as Indivior on the London Stock Exchange.In its first year as a public company, it made an operating profit of $346m on revenue of $1bn. Over the last year, the shares have risen by more than 130%.
Be glad you didn't
Fashion retailer Next (LSE: NXT) was once a favourite with investors. Between 2008 and late 2015, its shares rose by almost ten times. But since then, the company has lost its way as retail trends change. Last year proved difficult as customers deserted the chain, leading to multiple profit warnings. There's no relief in sight: last month, the firm warned that 2017 will be even tougher. The share price has slumped by over 40% in the past year.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
8 of the best houses for sale with annexesThe best houses with annexes – from a period property in the Lake District to a 13th-century house with a two-bedroom annexe in Saltwood, Kent
-
Zelenskyy moves to appease Donald Trump – what happens now?Ukraine’s president Volodymyr Zelenskyy is conceding ground to secure the least-worst deal possible, says Emily Hohler
-
Next’s results stand out against a tough retail backdropAnalysis FTSE 100 retailer Next is dealing well with the tough conditions on the high street, with rising profits and a plan that's working. Rupert Hargreaves looks at the numbers.
-
Why Next is the only retailer I’d want to own in my portfolioNews The retail sector is brutally competitive. But high street stalwart Next is exploiting and building on its significant competitive advantages, says Rupert Hargreaves.
-
Next shares soar as sales smash expectations – is the stock a buy?News High street and online retailer Next has reported a big rise in sales and profits. John Stepek looks at its performance and asks if it's worth buying Next shares.
-
Little cheer on the high streetFeatures Profit warnings from Debenhams and Mothercare are more evidence that traditional retailers are fighting a losing battle against nimbler online competitors, says Ben Judge.
-
Indivior’s miracle drug wears offFeatures Indivior’s opioid addiction treatment has been exposed to generic competition. Can the drugmaker fight back? Alice Gråhns reports.
-
Next: Out of fashionFeatures Clothing retailer Next has released gloomy results, yet the firm’s shares rallied strongly. Why? Ben Judge reports.
-
The end of an era for hedge fundsFeatures More than 1,000 hedge funds shut down last year – the most since the financial crisis. There are now fewer funds around than at any time since 2013. What’s going on?
-
Next faces its toughest year since 2008
Features The clothing retailer has long been a favourite of long-term investors, but now Next is facing tough times.
